Danielle Molinari Andrade

Danielle Molinari Andrade, MD, MSc, FRCPC

Dr. Andrade is the Medical Director of the Epilepsy Program at that University Health Network, University of Toronto. She is the founder and Director of Krembil Neuroscience Epilepsy Genetics Program. Dr. Andrade is also the Director of the Epilepsy Transition Program, a program in collaboration with The Hospital for Sick Children that helps promote coordinated, smooth and efficient transition from the pediatric to the adult health systems for patients with intractable epilepsy. She was the chair of the epilepsy implementation task force sub-group for the development of Guidelines for Transition in Epilepsy for the Province of Ontario. 
 
Dr. Andrade graduated in Medicine from Universidade Federal do Parana (Brazil) and completed her Neurology Residency at Hospital N.S. Gracas (Brazil). She then completed a Master of Sciences at The Hospital for Sick Children, University of Toronto, which was focused on “Protein Therapy for Unverricht-Lundborg Progressive Myoclonus Epilepsy”. Between 2004 and 2006 Dr. Andrade completed an Epilepsy and Clinical Electrophysiology Fellowship at Toronto Western Hospital, University of Toronto.
 
Dr. Andrade’s research interests are in the field of genetic epilepsies and their long-term outcome. Her team identified the first gene associated with SUDEP (sudden, unexpected death in epilepsy) in patients with non-syndromic epilepsy. Her team also discovered the genes responsible for different epilepsies, including Lennox-Gastaut syndrome, Jeavon’s syndrome, teenage-onset neuronal ceroid lipofuccinosis and progressive myoclonus epilepsy. 
 
Dr. Andrade leads UHN's adult Dravet Syndrome program. Along with her collaborators, she has determined that the majority of adults with Dravet syndrome develop early onset parkinsonian features. Her work in this area is now focused on examining the long-term outcome of seizures in Dravet patients treated with deep brain stimulation. 
 
Dr. Andrade’s work on genotype/phenotype correlations in adults with genetic epilepsies has shown that patients with 22q11.2 have an overall lower seizure threshold, even in the absence of genetic generalized epilepsy or structural epilepsy. Her research has also shown that more than 15% of adults with pediatric-onset epilepsy and intellectual disability have a pathogenic copy number variation in their genomes.
 
Dr. Andrade continues to collaborate on national and international initiatives to discover new genes that are associated with common and rare epilepsies, and to identify how these genes affect patient responses to therapy.

 

Neurology. 2011 Apr 12;76(15):1355-7
Andrade DM, Tai P, Dalmau J, Wennberg R
Arch Intern Med. 2010 Jul 26;170(14):1274; author reply 1275
Andrade DM, Vidigal PG, Eloi-Santos SM
Neurology. 2010 Mar 16;74(11):932-3
Tai P, Poochikian-Sarkissian S, Andrade D, Valiante T, del Campo M, Wennberg R
Can J Neurol Sci. 2010 Jan;37(1):141-4
Andrade DM, McAndrews MP, Hamani C, Poublanc J, Angel M, Wennberg R
Can J Neurosci Nurs. 2009;31(4):22-3
Poochikian-Sarkissian S, Tai P, del Campo M, Andrade DM, Carlen PL, Valiante T, Wennberg RA
Epilepsia. 2010 Jul;51(7):1314-6
Andrade DM, Hamani C, Lozano AM, Wennberg RA
Int J Neural Syst. 2009 Jun;19(3):213-26
Hamani C, Andrade D, Hodaie M, Wennberg R, Lozano A
Expert Opin Pharmacother. 2009 Jul;10(10):1549-60
Andrade DM, Hamani C, Minassian BA
Epilepsy Res. 2008 Feb;78(2-3):117-23
Hamani C, Hodaie M, Chiang J, del Campo M, Andrade DM, Sherman D, Mirski M, Mello LE, Lozano AM

Pages


Medical Director, Epilepsy Program, UHN
Krembil Neuroscience Director of Epilepsy Genetics Research Program, UHN
Director,  Epilepsy Transition Program, UHN
Associate Professor, Neurology, University of Toronto